The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Michaël J B van Baar; Annemarie B van der Aart; Klaas Hoogenberg; Jaap A Joles; Hiddo J L Heerspink; Daniël H van Raalte

doi:10.1177/2042018819865398

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Michaël J B van Baar, Annemarie B van der Aart, Klaas Hoogenberg, Jaap A Joles, Hiddo J L Heerspink, Daniël H van Raalte

Research output: Contribution to journal › Review article › peer-review

7 Downloads (Pure)

Abstract

Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.

Original language	English
Pages (from-to)	1-11
Number of pages	11
Journal	Therapeutic Advances in Endocrinology and Metabolism
Volume	10
DOIs	https://doi.org/10.1177/2042018819865398
Publication status	Published - Jul 2019

Keywords

GLP-1 receptor agonists
albuminuria
blood pressure
diabetic kidney disease
incretin-based therapies

Access to Document

10.1177/2042018819865398

2042018819865398Final published version, 687 KB

Cite this

@article{464b05a0023a4a08945f4044ca482775,

title = "The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists",

abstract = "Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.",

keywords = "GLP-1 receptor agonists, albuminuria, blood pressure, diabetic kidney disease, incretin-based therapies",

author = "{van Baar}, {Micha{\"e}l J B} and {van der Aart}, {Annemarie B} and Klaas Hoogenberg and Joles, {Jaap A} and Heerspink, {Hiddo J L} and {van Raalte}, {Dani{\"e}l H}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2019.",

year = "2019",

month = jul,

doi = "10.1177/2042018819865398",

language = "English",

volume = "10",

pages = "1--11",

}

TY - JOUR

T1 - The incretin pathway as a therapeutic target in diabetic kidney disease

T2 - a clinical focus on GLP-1 receptor agonists

AU - van Baar, Michaël J B

AU - van der Aart, Annemarie B

AU - Hoogenberg, Klaas

AU - Joles, Jaap A

AU - Heerspink, Hiddo J L

AU - van Raalte, Daniël H

N1 - Publisher Copyright: © The Author(s), 2019.

PY - 2019/7

Y1 - 2019/7

N2 - Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.

AB - Diabetic kidney disease (DKD) remains the main cause for chronic kidney disease (CKD) and end-stage kidney disease (ESKD) worldwide. Both CKD and ESKD lead to major increases in risk of cardiovascular disease and death in people with diabetes. Despite optimal management of lifestyle, glucose levels and hypertension, residual risk remains high, indicating that additional therapies to mitigate the burden of the disease are desired. In past decades, new treatment options for the management of diabetes have emerged, of which some have showed promising renoprotective potential. This review discusses current understanding of the renal effects of glucagon-like peptide receptor agonists and their potential use in prevention and treatment of DKD.

KW - GLP-1 receptor agonists

KW - albuminuria

KW - blood pressure

KW - diabetic kidney disease

KW - incretin-based therapies

U2 - 10.1177/2042018819865398

DO - 10.1177/2042018819865398

M3 - Review article

C2 - 31384419

SN - 2042-0188

VL - 10

SP - 1

EP - 11

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

ER -

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists

Abstract

Keywords

Access to Document

Fingerprint

Cite this